Latest International Sales News

Biome Australia Limited has reported its first net profit alongside a 41.6% jump in sales revenue, driven by strong domestic growth and expanding international partnerships.

Biome Australia Limited reports its first profitable year since 2018, driven by a 41.6% revenue increase and significant international growth.

McPherson’s Limited reported a 3.9% revenue decline to $139 million in FY25 amid a strategic shift to a pharmacy wholesaler model, posting a $15 million net loss but signaling moderate EBITDA growth ahead.

MyEco Group Ltd reported an 8.6% revenue increase to $15.7 million in FY25, driven by strong growth in its MyEco® branded products and improved margins. The company cut its net loss by nearly half, supported by operational restructuring and expanding market presence.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.

Lark Distilling Co. Ltd reported a 3% revenue increase to $17.17 million for FY25, driven by whisky sales growth and a major brand restage, while losses widened significantly due to increased marketing spend and operational investments.

XRF Scientific Limited reported a record profit for FY25, driven by strong mining sector demand and international sales growth, alongside strategic acquisitions that bolster its market position.

XRF Scientific has reported a record full-year result for FY2025, with net profit rising 17% to $10.4 million and a 15% increase in its fully franked dividend. Strong global mining demand and recurring revenue streams underpin the company’s growth.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.

Vmoto reports a sharp 44% decline in 2Q25 sales driven by China’s slowdown but counters with strategic UK investment and a new Uber partnership to electrify European delivery fleets.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Murray Cod Australia reports a near tripling of biomass and strong sales growth in Q4 FY25, while advancing key certifications and expanding market reach.